Boston Scientific’s next move
The cardiovascular specialist needs to buy its way to growth – and it has marked an interest in a handful of smaller companies.
March medtech merger madness
High asset prices and a need to release the pandemic’s brake on growth force medtechs to splash the cash.
Medtech’s haves and have-nots
Medtronic’s quarterly results yesterday might presage a recovery, and some groups are in dire need of one.
